Assuming the doxo synergy is just as validated by the MOA as other drug synergies are, then if the doxo synergy were to fail, isn't it likely that other synergies would also be likely to fail?
In that case, pursuing many synergies in parallel would probably be a waste of money. Wouldn't it be better to first understand why the doxo synergy failed contrary to prevailing preclinical/MoA evidence that it should work, rather than hoping to blindly strike a synergy that does work but we don't understand why/how?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)